Companies · Other Health Care

ObjectiveHealth, Inc.

FRANKLIN · Other Health Care

Diligence memoA one-page analyst read on ObjectiveHealth, Inc. — recommendation, valuation, rhythm, risks.
$68.0M
Total raised · real
4
Rounds
1.0×
Latest step-up
Top 7%
Sector rank · raised
Series C
Latest stage · inferred · Thu Mar 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

ObjectiveHealth, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.42× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
  • Within the normal band (142% of peer median) for its niche.
Active
  • Last raise 15 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

ObjectiveHealth, Inc. is one of 5376 Other Health Care companies tracked from FRANKLIN. By capital raised it ranks among the largest (ahead of 94% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2025-04-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2019-12-09 Raised $6.6M (real) Modeled valuation $134M (est)$6.6M$134MSeries A2019Series A · 2021-03-10 Raised $7.1M (real) Modeled valuation $112M (est)$7.1M$112MSeries A2021Series A · 2022-11-10 Raised $7.0M (real) Modeled valuation $61M (est)$7.0M$61MSeries A2022Series C · 2025-03-20 Raised $47M (real) Modeled valuation $321M (est)$47M$321MSeries C2025Series C · 2025-04-21 Raised $47M (real) Modeled valuation $314M (est)$47M$314MSeries C2025+$7.1M+$7.0M+$47M+$47MCumulative $115M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.6M · 2019
Series A extension$7.1M · 2021
Series A extension$7.0M · 2022
Series C$47.2M · 2025no Series B on file
Series C extension$47.2M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$321.0M
Base estimate est.
$171.7M
Conservative case
$441.8M
Upside case
$314.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $133.6M · 2019-12-092019Series A · modeled $112.2M · 2021-03-10Series A · modeled $60.6M · 2022-11-10Series C · modeled $321.0M · 2025-03-20Series C · modeled $313.8M · 2025-04-212025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
1.3 yr
Elapsed time used
1.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$12.7M/yr
Capital velocity
6.6 yr
On record since
2019
First round
5
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 28× above median
This company$68.0M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.0× above median
This company$47.2M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 15× above median
This company$321.0M
Sector median$22.1M

Raised more than 94% of sector peers (real $). Modeled value above 91% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 20.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)RESTOR3D, Inc. · Series C Raised $239.2M · modeled $522.0M (est)ByHeart, Inc. · Series C Raised $378.4M · modeled $493.2M (est)SpyGlassPharma, Inc. · Series C Raised $134.8M · modeled $484.8M (est)VantAI Holdings, Inc. · Series C Raised $86.3M · modeled $475.3M (est)BioIntelliSense, Inc. · Series C Raised $140.0M · modeled $328.7M (est)VentureMed Group, Inc. · Series C Raised $59.8M · modeled $288.0M (est)Exo Imaging, Inc. · Series C Raised $169.6M · modeled $284.4M (est)InspireMD, Inc. · Series C Raised $117.2M · modeled $248.1M (est)Fonar, Llc · Series C Raised $51.2M · modeled $228.9M (est)MicroTransponder, Inc. · Series C Raised $117.7M · modeled $223.2M (est)Fourth Edge LLC · Series C Raised $119.7M · modeled $221.8M (est)ObjectiveHealth, Inc. (this company) Raised $68.0M · modeled $321.0M (est)ObjectiveHealth, Inc.
CompanyStageRaised · realValue · estvs peer med.
RESTOR3D, Inc.Series C$239.2M$522.0M2.31×
ByHeart, Inc.Series C$378.4M$493.2M2.18×
SpyGlassPharma, Inc.Series C$134.8M$484.8M2.14×
VantAI Holdings, Inc.Series C$86.3M$475.3M2.10×
BioIntelliSense, Inc.Series C$140.0M$328.7M1.45×
ObjectiveHealth, Inc. this companySeries C$68.0M$321.0M1.42×
VentureMed Group, Inc.Series C$59.8M$288.0M1.27×
Exo Imaging, Inc.Series C$169.6M$284.4M1.26×
InspireMD, Inc.Series C$117.2M$248.1M1.10×
Fonar, LlcSeries C$51.2M$228.9M1.01×
MicroTransponder, Inc.Series C$117.7M$223.2M0.99×
Fourth Edge LLCSeries C$119.7M$221.8M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.6M2019-12-09$30.1M$133.6M90%
Series A$7.1M2021-03-10$32.4M$112.2M90%
Series A$7.0M2022-11-10$31.8M$60.6M90%
Series C$47.2M2025-03-20$314.9M$321.0M90%
Series C$47.2M2025-04-21$314.9M$313.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.6M2019-12-09
    • First recorded raise — entered as Series A.
    • 15 investors on this round.
  2. Series A$7.1M2021-03-10
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 8 investors on this round.
  3. Series A$7.0M2022-11-10
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 9 investors on this round.
  4. Series C$47.2M2025-03-20
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round 6.7× larger than the prior — scaling up.
    • 6 investors on this round.
  5. Series C$47.2M2025-04-21
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 6 investors on this round.
Intelligence
2026 ~Q3
Modeled next raise · ~16mo cadence
$47.2M
Modeled next size est.range $47.2M$75.6M
1.0×
Last step-up
$12.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Austin Poole4 other2021-03
Christopher Booker4 other2019-12
David Fox3 other2019-12
Navid Farzad3 other2019-12
Gerry Andrady2 other2019-12
Donald Lazas1 other2019-12
James Porter1 other2025-03
Van Johnson1 other2025-03
Ben Cons2025-03
Bill Taaffe2019-12
Charlie Jordan2025-03
Colleen Hoke2019-12
Duncan Reek2025-03
Josh O'Rourke2025-03
Kumar Muthalagappan2025-03
Sonny Terrill2025-03
Sophie Bower-Straziota2025-03
Steve Clemons2025-03
Stu Warren2019-12
Registry & provenance

ObjectiveHealth, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1796886
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Calypso Medical Technologies IncOther Health CareSeries C$69.5M$171.5Msame sector · same stage
TW-NHME Holdings Corp.Other Health CareSeries C$64.3M$171.5Msame sector · same stage
VentureMed Group, Inc.Other Health CareSeries C$59.8M$288.0Msame sector · same stage
Cytrellis Biosystems, Inc.Other Health CareSeries C$82.7M$182.0Msame sector · same stage
ViaLase, Inc.Other Health CareSeries C$84.1M$395.6Msame sector · same stage
Dental Implant Holdings, LLCOther Health CareSeries C$53.7M$228.6Msame sector · same stage
VantAI Holdings, Inc.Other Health CareSeries C$86.3M$475.3Msame sector · same stage
Fonar, LlcOther Health CareSeries C$51.2M$228.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
CoreHealth Solutions, LLCOther Health CarePre-Seed$8.3M87%
BaseHealth, Inc.Other Health CareSeries A$91.7M86%
IncludeHealth, Inc.Other Health CareSeries A$13.5M86%
CoreMedica Laboratories Inc.Other Health CareSeed$61.1M86%
Intellihealth, Inc.Other Health CareSeries B$22.6M85%
UpHealth, Inc.Other Health CareSeries A$34.7M84%
eHealth, Inc.Other Health CareSeries D+$4.4B84%
BioMedx Group, Inc.Other Health CarePre-Seed$14.0M84%
Frequently asked
How much funding has ObjectiveHealth, Inc. raised?
ObjectiveHealth, Inc. has raised approximately $68.0M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is ObjectiveHealth, Inc.'s estimated valuation?
Provath's modeled valuation for ObjectiveHealth, Inc. is approximately $321.0M (modeled range $171.7M–$441.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ObjectiveHealth, Inc. at?
ObjectiveHealth, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Thu Mar 20.
What does ObjectiveHealth, Inc. do and where is it based?
ObjectiveHealth, Inc. operates in the Other Health Care sector, based in FRANKLIN.
Explore related

See where ObjectiveHealth, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ObjectiveHealth, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.